China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a Phase III clinical study for GZR4, its Category 1 therapeutic biologic product. GZR4 is an investigational ultra-long-acting insulin designed for once-per-week subcutaneous injection to treat diabetes.
Drug Profile
GZR4 aims to provide a convenient weekly dosing option for diabetes patients, addressing the need for improved adherence to insulin therapy. The Phase III study will evaluate the efficacy and safety of GZR4 in a large patient population.
Market Context
The most advanced weekly insulin product is Novo Nordisk’s Icodec (insulin 287), which received marketing approval in the European Union in March 2022 and in China in June 2022. Eli Lilly’s recombinant basal insulin Fc (LY3209590) completed Phase III trials in September 2022 with positive results, adding to the competitive landscape of weekly insulin therapies.-Fineline Info & Tech
Leave a Reply